A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension who are not controlled on RAASi mono-therapy being switched.
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Amlodipine/telmisartan (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 31 May 2012 Planned number of patients changed from 502 to 650 as reported by European Clinical Trials Database record.
- 28 Jun 2011 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.